133 related articles for article (PubMed ID: 10518983)
1. [Polychemotherapy versus monotherapy in metastatic breast carcinoma].
Tanner J; Dunst J
Strahlenther Onkol; 1999 Sep; 175(9):471. PubMed ID: 10518983
[No Abstract] [Full Text] [Related]
2. Increased dosage of epirubicin and mitomycin-C for the treatment of metastatic adenocarcinoma of unknown primary site.
Polyzos A; Koulentianos E; Tzianoumis L; Sfikakis P
J Chemother; 1989 Jul; 1(4 Suppl):1185-6. PubMed ID: 16312826
[No Abstract] [Full Text] [Related]
3. Concomitant versus sequential administration of epirubicin and paclitaxel as first-line therapy in metastatic breast carcinoma: results for the Gruppo Oncologico Nord Ovest randomized trial.
Conte PF; Guarneri V; Bruzzi P; Prochilo T; Salvadori B; Bolognesi A; Aldrighetti D; Venturini M; Rosso R; Mammoliti S; Carnino F; Giannessi P; Costantini M; Moyano A; Baldini E;
Cancer; 2004 Aug; 101(4):704-12. PubMed ID: 15305399
[TBL] [Abstract][Full Text] [Related]
4. Phase III study of intravenous vinorelbine in combination with epirubicin versus epirubicin alone in patients with advanced breast cancer: a Scandinavian Breast Group Trial (SBG9403).
Ejlertsen B; Mouridsen HT; Langkjer ST; Andersen J; Sjöström J; Kjaer M;
J Clin Oncol; 2004 Jun; 22(12):2313-20. PubMed ID: 15197192
[TBL] [Abstract][Full Text] [Related]
5. Cardiotoxicity of epirubicin versus doxorubicin: cost and clinical results.
Ventura GJ
J Clin Oncol; 2005 Apr; 23(12):2873; author reply 2873-4. PubMed ID: 15838014
[No Abstract] [Full Text] [Related]
6. Anthracycline cardiotoxicity: one size does not fit all!
Hershman DL; Neugut AI
J Natl Cancer Inst; 2008 Aug; 100(15):1046-7. PubMed ID: 18664649
[No Abstract] [Full Text] [Related]
7. Weekly epirubicin and paclitaxel with granulocyte colony-stimulating factor support in previously untreated metastatic breast cancer patients: a phase II study.
Nisticò C; Bria E; Cuppone F; Fornier M; Sperduti I; Carpino A; Pace A; Cognetti F; Terzoli E
Anticancer Drugs; 2007 Jul; 18(6):687-92. PubMed ID: 17762397
[TBL] [Abstract][Full Text] [Related]
8. Second and third line chemotherapy in advanced breast cancer.
Alexopoulos A; Rigatos G; Stavrinidis E; Stavrakakis J; Scartsilas C; Papacharalambous A
J Chemother; 1989 Jul; 1(4 Suppl):1189-90. PubMed ID: 16312828
[No Abstract] [Full Text] [Related]
9. New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients.
Ryberg M; Nielsen D; Cortese G; Nielsen G; Skovsgaard T; Andersen PK
J Natl Cancer Inst; 2008 Aug; 100(15):1058-67. PubMed ID: 18664656
[TBL] [Abstract][Full Text] [Related]
10. Chemotherapy and concomitant irradiation in inflammatory breast cancer.
Tubiana-Mathieu N; Lejeune C; Bonnier P; Genet D; Adjadj DJ; Berda JF; Muracciole X; Delaby F; Clavere P; Benyoub A; Rhein B; Juin B; Piana L
Anticancer Res; 2001; 21(4B):3061-7. PubMed ID: 11712811
[TBL] [Abstract][Full Text] [Related]
11. Folinic acid, 5-fluorouracil and mitomycin C in metastatic breast cancer patients previously treated with at least two chemotherapy regimens.
Francini G; Petrioli R; Messinese S; Pozzessere D; Marsili S; Correale P; Sabatino M; Fiaschi AI
Cancer Chemother Pharmacol; 2002 Oct; 50(4):271-6. PubMed ID: 12357300
[TBL] [Abstract][Full Text] [Related]
12. Epirubicin for adjuvant therapy in node-positive breast cancer.
Med Lett Drugs Ther; 2000 Feb; 42(1071):12-3. PubMed ID: 10725968
[No Abstract] [Full Text] [Related]
13. Epirubicin as adjuvant therapy in breast cancer.
Earl H; Iddawela M
Expert Rev Anticancer Ther; 2004 Apr; 4(2):189-95. PubMed ID: 15056049
[TBL] [Abstract][Full Text] [Related]
14. Simultaneous radiochemotherapy in cervical cancer: recommendations for chemotherapy.
Dunst J; Haensgen G
Strahlenther Onkol; 2001 Dec; 177(12):635-40. PubMed ID: 11789401
[TBL] [Abstract][Full Text] [Related]
15. [Safety and efficacy of weekly paclitaxel followed by FEC100 as primary systemic therapy for breast cancer].
Naito K; Oura S; Yoshimasu T; Tamaki T; Ohta F; Nakamura R; Shimizu Y; Kiyoi M; Hirai Y; Miyasaka M; Okamura Y
Gan To Kagaku Ryoho; 2009 Feb; 36(2):251-4. PubMed ID: 19223740
[TBL] [Abstract][Full Text] [Related]
16. [Salvage chemotherapy with mitomycin C and vindesine in metastatic carcinoma of the breast].
Ardizzoni A; Lionetto R; Repetto L; Pronzato P; Rosso R
G Ital Chemioter; 1985; 32(1):61-2. PubMed ID: 3938418
[No Abstract] [Full Text] [Related]
17. [Evaluation of two different regimens as neoadjuvant chemotherapy for breast cancer].
Yang D; Tong F; Cao Y; Liu P; Zhou B; Liu H; Qiao X; Zhang J
Zhonghua Zhong Liu Za Zhi; 2002 May; 24(3):303-5. PubMed ID: 12515634
[TBL] [Abstract][Full Text] [Related]
18. A case of manic episode during treatment with 5-fluorouracil, epirubicin and cyclophosphamide for breast cancer.
Pacchiarotti I; Mazzarini L; Pellegrini P; Venturelli V; Sani G; Sánchez-Moreno J; Mancinelli I; Tatarelli R; Kotzalidis GD; Girardi P
Gen Hosp Psychiatry; 2007; 29(5):461-3. PubMed ID: 17888816
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant high-dose chemotherapy with epirubicin and ifosfamide in nodal positive breast cancer.
Lüftner D; Wagner K; Dingeldein G; Haas A; Sezer O; Mergenthaler HG; Wernecke KD; Possinger K
Anticancer Res; 1999; 19(4C):3583-90. PubMed ID: 10629656
[TBL] [Abstract][Full Text] [Related]
20. Meglumine Eicosapentaenoic acid (MeEPA) a new soluble omega-3 fatty acid formulation: in vitro bladder cancer cytotoxicity tests in combination with epirubicin and mitomycin.
Mackie SJ; Sharma DM; Cooper AJ; Harris NM; Lwaleed BA
Prostaglandins Leukot Essent Fatty Acids; 2006 Dec; 75(6):367-73. PubMed ID: 16930970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
